Carbon-11-PK-11195 - Genzyme

Drug Profile

Carbon-11-PK-11195 - Genzyme

Alternative Names: (R)-[11C]PK11195; [11C]PK11195

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Sanofi
  • Developer Sanofi; VU University Medical Center; Weill Cornell Medical College
  • Class Diagnostic agents
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Multiple sclerosis
  • No development reported Brain disorders; Brain injuries

Most Recent Events

  • 19 Jan 2017 (R)-[11C]PK11195 is still in clinical trials for Multiple sclerosis (Diagnosis) in USA (NCT02207075)
  • 19 Jan 2017 No development reported - Phase-I for Brain disorders (Diagnosis) in Netherlands (unspecified route)
  • 19 Jan 2017 No development reported - Phase-I for Brain injuries (Diagnosis) in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top